Dichiara John 4

Accession 0001140361-09-001639

CIK 0000883697other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 6:40 PM ET

Size

26.8 KB

Accession

0001140361-09-001639

Form 4

Period: 2009-01-16

SR. VICE PRESIDENT

Transactions

Conversion
Common Stock
2009-01-16$3.00/sh+1,035$3,105→ 3,849 total(indirect: by Ariana Dichiara)
Conversion
Convertible Notes
2009-01-16$500.00/sh→ 0 total(indirect: by Ariana Dichiara)
Exercise: $3.00From: 2008-12-04Exp: 2009-07-24→ Common Stock (169 underlying)
Purchase
Warrants
2009-01-16+423→ 423 total(indirect: by Ariana Dichiara)
Exercise: $1.20From: 2009-01-16Exp: 2014-01-16→ Common Stock (423 underlying)
Purchase
Common Stock
2009-01-16$3.50/sh+2,814$9,849→ 2,814 total(indirect: by Ariana Dichiara)
Conversion
Common Stock
2009-01-16$3.00/sh+1,035$3,105→ 3,849 total(indirect: by Michael Dichiara)
Conversion
Convertible Notes
2009-01-16$500.00/sh→ 0 total(indirect: by Michael Dichiara)
Exercise: $3.00From: 2008-12-04Exp: 2009-07-24→ Common Stock (169 underlying)
Purchase
Common Stock
2009-01-16$3.50/sh+2,814$9,849→ 2,814 total(indirect: by Michael Dichiara)
Conversion
Convertible Notes
2009-01-16$2500.00/sh→ 0 total(indirect: by Ariana Dichiara)
Exercise: $3.00From: 2008-07-24Exp: 2009-07-24→ Common Stock (867 underlying)
Conversion
Convertible Notes
2009-01-16$2500.00/sh→ 0 total(indirect: by Michael Dichiara)
Exercise: $3.00From: 2008-07-24Exp: 2009-07-24→ Common Stock (867 underlying)
Purchase
Warrants
2009-01-16+423→ 423 total(indirect: by Michael Dichiara)
Exercise: $1.20From: 2009-01-16Exp: 2014-01-16→ Common Stock (423 underlying)

Holdings

Footnotes (5)

[F1]Represents the number of shares issued upon conversion of the convertible notes at $3.00 per share and such conversion amount included the principal amount and any accrued and unpaid interest on the notes. Some convertible notes were originally convertible at $0.15 per share, but the conversion price increased to $3.00 per share after the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
[F2]Represents the principal amount of the convertible notes purchased and does not include any accrued and unpaid interest on the notes.
[F3]Represents the number of shares of common stock into which the notes are convertible and such conversion amount includes the principal amount and any accrued and unpaid interest on the notes.
[F4]Such conversion price was increased from $0.15 to $3.00 per share following the 1 for 20 reverse split of the Company's common stock on November 29, 2008.
[F5]The warrants were issued pursuant to a Subscription Agreement, dated January 16, 2009, by and between ReGen Biologics, Inc. (the "Company") and each of the investors named therein. Each investor acquired common stock of the Company at $3.50 per share and without additional consideration, the Company provided 15% warrant coverage to each investor exercisable for additional shares of common stock.

Documents

1 file

REGEN BIOLOGICS INC

CIK 0000883697

Entity typeother